GlobeNewsWire
22 Jul 2026, 12:40 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Akari Therapeutics has entered a strategic research collaboration with Whitehawk Therapeutics to evaluate dual payload synergy using Akari's PH1 platform and Whitehawk's TOP1i ADC platform. — Strategic partnerships with other biotech firms serve as external validation of a company's proprietary technology and can accelerate the path to clinical development.
+0.60Akari's lead candidate, AKTX-101, is currently in IND-enabling studies with a goal to start First-In-Human trials by mid-2027. — Establishing a concrete timeline for human trials provides a catalyst for future valuation, though the 2027 date is relatively far off.
+0.40The company is developing a second ADC candidate, AKTX-102, which targets the CEACAM5 tumor antigen. — Expanding the pipeline beyond a single lead candidate reduces binary risk and increases the total addressable market for the PH1 payload.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company announced a strategic collaboration and highlighted the growth potential of its proprietary PH1 platform and lead candidates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
